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To counter the poor aqueous solubility of itraconazole (ITC), its sulfate salt (ITCSUL) was
synthesized and characterized by 1H NMR, MS, FTIR, DSC, XRPD, DLS and SEM. Antifungal
properties of ITCSUL were confirmed against different fungal pathogens by broth micro-
dilution method. Enhanced solubility of the salt in various pharmaceutical solvents was
observed. Approximately 5.5 fold increase in percentage drug release from ITCSUL than
that of ITC in 3 h was observed. Further, the physical mixtures of ITCSUL with two cy-
clodextrins; b-cyclodextrin (b-CD) and HP-b-cyclodextrin (HP-b-CD) were prepared in 3 M
ratios. The in vitro release studies of CD mixtures of ITC and ITCSUL exhibited markedly
enhanced dissolution in comparison to ITC and ITCSUL respectively. The promising in vitro
performance of ITCSUL and ITCSUL CD mixtures along with advantage of expedient
preparation suggest their potential applications in designing a better oral drug delivery
system.
ª 2013 Shenyang Pharmaceutical University. Production and hosting by Elsevier B.V. All
rights reserved.1. Introduction
Among the routes of administration, oral drug delivery re-
mains the preferred route since antiquity due to its simplicity
and patient compliance. However, some drugs with poor
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oping successful oral drug delivery of these drugs [1]. It has
been reported that approximately 45% of the top 200 oral drug
products from the US, Britain, Spain and Japan are poorly
water soluble [2]. This emphasizes the requirement of new
water soluble active pharmaceutical ingredients and better
formulation strategies for existing drug molecules.s (U.I.P.S.), Panjab University, Chandigarh 160014, India. Tel.: þ91
sity
ersity. Production and hosting by Elsevier B.V. All rights reserved.
a s i a n j o u rn a l o f p h a rma c e u t i c a l s c i e n c e s 9 ( 2 0 1 4 ) 8e1 6 9Itraconazole (ITC) is a broad spectrum antifungal agent
used in the treatment of infections caused by a variety of
pathogenic fungi. It possesses better safety profile than other
triazole counterparts like fluconazole, ravuconazole and pos-
conazole [3,4]. Therefore, ITC is indicated for the treatment of
fungal infections like blastomycosis, histoplasmosis,
including chronic cavitary pulmonary disease and dissemi-
nated non-meningeal histoplasmosis, aspergillosis (pulmo-
nary and extrapulmonary) in both immunocompromised and
nonimmunocompromised patients [5e7]. Moreover, itraco-
nazole is known to be less nephrotoxic than Amphotericin B,
therefore it could also be indicated in patients who are intol-
erant to or refractory to Amphotericin B therapy [8].
However, ITC being a BCS Class II drug possesses a poor
aqueous solubility which results in its inadequate and vari-
able absorption which in turn results in erratic bioavailability
[9,10]. Owing to its safety profile and broad spectrum anti-
fungal efficacy, there is a strong need to counteract the
drawback of poor solubility of ITC to render this valuable
molecule more utilizable especially through oral route.
The attempts in recent years to enhance the solubility and
the dissolution profile of ITC include solid dispersion method
[11], micro- and nanoparticulate systems [12] and emulsified
systems [13]. However, these techniques mostly require
dedicated plant facility and in addition are also less favored
due to higher cost factors associated with their raw materials
and equipment. In addition, the manufacture of commercial
ITC capsules involves use of toxic solvents and several tedious
unit operations [14].
Salt formation, alternatively, is a convenient and inex-
pensive technique which can be used to tune the physico-
chemical properties like aqueous solubility and hence
bioavailability of an ionizable drug due to polar character
imparted by the counter anions. A recent report describes
dihydrochloride salt of itraconazole, which provided better
solubility and dissolution performance than the free base drug
itself [15]. However, this salt is not expected to work accord-
ingly in in vivo conditions due to chloride common ion effect
as explained by Miyazaki et al. [16]. This prompted us to
investigate the prospect of sulfate salt of ITC. The salt was
prepared by a convenient addition reaction of itraconazole
and sulfuric acid. The characterization was performed using
different spectral and thermal techniques. The salt was tested
for any loss in antifungal efficacy against four fungal patho-
gens. Also, the dissolution performance of the salt by pre-
paring its physical mixtures with two cyclodextrins namely,
beta-cyclodextrin (b-CD) and hydroxypropyl-beta-
cyclodextrin (HP-b-CD) was studied.2. Materials and methods
2.1. Materials
2.1.1. Chemicals and reagents
ITC was provided as a gift sample by Nosch Labs Pvt Ltd,
Hyderabad, India. Commercial ITC capsules (Candistat,
100 mg/capsule, Merck India Ltd.) were procured from local
market.2.1.2. Organisms and culture media
Aspergillus fumigates, Microsporum canis, Microsporum gypsum
and Trichophyton rubrum were procured form Microbial Type
Culture Collection (MTCC), Institute of Microbial Technology,
Chandigarh.
2.1.3. Composition of media for A. fumigates (Czapek
media)
Czapek concentratewas prepared by dissolving sodiumnitrite
(30 g), potassium chloride (5.0 g), magnesium sulfate hepta-
hydrate (5.0 g) and ferrous sulfate heptahydrate (0.1 g) in up to
100 ml of distilled water. The prepared Czapek concentrate
(10 ml) was dissolved in distilled water along with dipotas-
sium hydrogen phosphate (1.0 g), yeast extract (5.0 g), sucrose
(30.0 g) and agar (15.0 g) to provide Czapek media. The final
volume of the media was adjusted to 1000 ml by adding
appropriate quantity of distilled water.
2.1.4. Composition of media for M. canis, M. gypsum and
T. rubrum (Sabouraud media)
Special peptone (10.0 g), dextrose (20.0 g) and agar (15.0 g) were
dissolved in water added to make the volume to 1000 ml.2.2. Methods
2.2.1. Synthesis of itraconazolium sulfate salt
The sulfate salt of ITC was synthesized by acid addition
method already illustrated in our previous report [17]. Briefly,
a solution of ITC (5 g, 7.09 mmol) in chloroform (20 ml) was
refluxed with methanolic solution 50% (v/v) of sulfuric acid
(7.09 mmol) for 15 min. Then the reaction mixture was
washed with water using separating funnel and dried over
anhydrous sodium sulfate followed by evaporation of chlo-
roform under reduced pressure. The resulting pale white
residue was dissolved in methanol and reprecipitated by
addition of cold water. The precipitates were filtered and
dried under vacuum.
2.2.2. Characterization of ITCSUL
The following analytical techniques were used for the char-
acterization of the prepared salt:
2.2.2.1. 1H NMR spectroscopy. NMR spectra were recorded on
400 MHz Bruker FT-NMR spectrometer using tetramethylsi-
lane as internal standard and the chemical shifts are reported
in d units. Deuterated chloroform (CDCl3) was used as a sol-
vent [17].
2.2.2.2. Fourier transform infrared spectroscopy (FTIR). FTIR
absorption spectra were recorded using FTIR spectrometer
(Perkin Elmer Co., Waltham, USA). KBr disks of the samples
were prepared and scanning was performed over a range of
500e4000 cm1 with a resolution of 4 cm1.
2.2.2.3. Mass spectrometry (MS). Mass spectrograph was ob-
tained by LCQ mass spectrometer (Finnigan MAT, UK) in At-
mospheric Pressure Chemical Ionization (APCI) mode with an
inner temperature of 200 C. Samples were dissolved in
methanol, filtered (0.45 mm), and analyzed in the range of
a s i a n j o u r n a l o f p h a rma c e u t i c a l s c i e n c e s 9 ( 2 0 1 4 ) 8e1 6100e1000 m/z. Data interpretation was performed using X’Cal-
ibur software [17].
2.2.2.4. Differential scanning calorimetry (DSC). DSC analysis
was performed usingMettler Toledo 821e DSC (Mettler Toledo,
Switzerland) operating with STARe software version Solaris
2.5.1 (Mettler Toledo, Switzerland). Temperature axis and cell
constant were calibrated using indium. Samples were heated
at 10 C/min over the temperature range of 25e400 C under
dry nitrogen flow (80 ml/min) in pin-holed aluminum pans.
2.2.2.5. X-ray powder diffraction (XRPD). The XRPD patterns
of ITC and ITCSUL were determined using X-ray diffractom-
eter (PANalytical’s X’Pert Pro, Almelo, Netherlands) with CuKa
radiation, voltage 40 KV, current 60 mA, scan range 3e50 2q
and scan rate 4/min.
2.2.2.6. Scanning electron microscopy (SEM). SEM was per-
formedusing a Jeol Scanningmicroscope (Jeol Inc., Japan)with a
15kVacceleratingvoltage.Thesurfacesofsamples forSEMwere
previously made electrically conductive in a sputtering appa-
ratus (Jeol FineCoat, ion sputter, JFC-1100, Japan)byevaporation
of gold. Magnifications of 1000 and 5000 were used.
2.2.2.7. Hot stage microscopy (HSM). HSM was carried out
using Zeiss Axioplan-2 microscope (Microptic, Netherlands)
fitted with Linkam 44 hot stage THMS600 (Linkam Scientific
Instruments, UK). Images were captured using attached
Nikon, Eclipse 80i camera. The samples were mounted in air/
silicone oil and heated from 25 to 375 C.
2.2.2.8. Dynamic light scattering (DLS). Themean particle size
and size distribution of ITC and ITCSUL powders were deter-
mined by dynamic light scattering in Mastersizer 2000S
(Malvern Instruments Ltd.,Worcester, UK). Dry samples of ITC
and ITCSUL (3 g) were analyzed using single narrow analysis
mode for a size range of 0.1e2000 mm.
2.2.3. Flow properties
The parameters governing flow properties of ITCSUL were
calculated using US Pharmacopoeia (2007) methods. The bulk
volume of the undisturbed powder when filled in a 50 ml
graduated cylinder was measured and bulk density (BD) was
calculated. Then the cylinder was tapped for around 500
times and final volume indicated tapped volume of the
powder which provided tapped density (TD). Hausner’s
ratio and compressibility index were calculated using
Equations (1) and (2).
Hausners ratio ¼ TD=BD (1)
Compressibility index ¼ 100ðTD BDÞ=TD (2)
2.2.4. UV spectrophotometric method development
Various standards (2e25 mg/ml) were prepared from a 100 mg/
ml stock solution of ITC and ITCSUL in simulated gastric fluid
(SGF) without pepsin. These standards were subsequently
used to prepare calibration curves of the drug and the salt at
lmax 254 nm. The method was validated with respect to line-
arity, accuracy, and precision.2.2.5. Solubility study
Solubility study was performed by method described by Yu
et al., 1999 [18]. Briefly, an excess amount of each sample was
added in 5 ml of solvent taken in a 25 ml conical flask and
shaken horizontally in shaker bath at 37  1 C for 72 h. The
samples were filtered through 0.45 mm membrane filter, suit-
ably diluted and analyzed spectrophotometrically.
2.2.6. Antifungal susceptibility test
Broth microdilution method has been suggested for the
determination of minimum inhibitory concentration (MIC) of
antifungal agents [19]. Filter sterilized stock solutions of ITC
and ITCSUL were prepared in dimethyl sulfoxide. The wells of
sterilizedmicroplates were filled with sterile media 280 ml and
10 ml of inocula were added in each well and mixed thor-
oughly. Various strengths of filter sterilized solutions (10 ml) of
ITC and ITCSUL were poured in the wells to make their final
concentration of drug in 0.03125e16 mg/ml range. Microplates
were incubated at 25 C for 5 days. The MIC was defined as
“the lowest concentration that produced prominent inhibition
of visual growth”.2.2.7. Preparation of cyclodextrin physical mixtures
The physical mixtures were prepared by screening together
repetitively (until homogenous) 500 mg of ITC (or 569.5 mg of
ITCSUL) with 804.3, 1608.5 and 2412.8 mg of b-CD and 1092.3,
2184.7 and 3277mg of HP-b-CD for preparing 1:1, 1:2 and 1:3 M
ratios respectively. The 1:1, 1:2 and 1:3 physical mixtures of
ITC with b-CD will be referred to as ITC-b1, ITC-b2 and ITC-b3
while those with HP-b-CD will be referred to as ITC-HP-b1,
ITC-HP-b2 and ITC-HP-b3 respectively. Correspondingly the
1:1, 1:2 and 1:3 physical mixtures of ITCSUL with b-CD will be
denoted as ITCSUL-b1, ITCSUL-b2 and ITCSUL-b3 whereas
those with HP-b-CDwill be designated ITCSUL-HP-b1, ITCSUL-
HP-b2 and ITCSUL-HP-b3 respectively.2.2.8. Dissolution testing
The USP paddle method was employed for the in vitro disso-
lution studies using 900 ml of enzymeless simulated gastric
fluid (SGF) having pH 1.2  0.02, maintained at 37  1 C and
stirred at 100 rpm. The amount of ITC taken for the study was
100 mg whereas that for ITCSUL and the cyclodextrin mix-
tures of ITC and ITCSUL takenwere 100mg drug equivalent. At
predetermined intervals, 5 ml of the samples were taken with
replacements, filtered through a 0.45 mmmembrane filters and
spectrophotometrically analyzed at 254 nm. The study was
carried out in triplicate.
The percent drug released (in 180 min) from ITC and ITC-
SULwere compared bymeans of two-way ANOVA followed by
Tukey’s test using statistical software (GraphPad Prism 5).
P < 0.001 was denoted for statistical significance.
In addition, the pharmacokinetic parameters like per-
centage drug dissolution in 10 min (DP10) and half-life of
release (T50%) were used to evaluate improvement of dissolu-
tion rate of ITCSUL and ITCSUL CD physical mixtures as
compared to ITC as well as marketed ITC capsules.
Also, dissolution efficiency (DE%) at 180minwas utilized to
assess the enhancement in extent of dissolution. This is
termed as the area under the dissolution curve up to a certain
Fig. 1 e Synthetic scheme of itraconazolium sulfate (equimolar amounts of ITC and sulfuric acid were taken).
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dissolution (Y100), over the same time period [20]. This is







where, Y ¼ %age of dissolved drug, t ¼ given time interval.
The dissolution profiles of ITCSUL as well as physical
mixtures with CDs were compared against dissolution profile
of commercial ITC capsule using the FDA approved model
independent approach of similarity factor [21], which is














where, n¼ number of time points, Rt¼ dissolution value of the
reference (prechange) batch at time t, Tt ¼ dissolution value of
the test (postchange) batch at time t.Fig. 2 e Mass spectrum of ITCSUL.3. Results and discussion
The salt was preparedwith a reaction yield of 90%. The results
of various spectral and thermal characterization techniques
have been enlisted below. The proposedminimum energy ball
and stick model structure of the drug salt has been shown in
Fig. 1.3.1. 1H NMR spectrum
The two peaks representing eight piperazine ring protons
originally encountered from d 3.15e3.17 ppm and
d 3.22e3.24 ppm in ITC spectrawere shifted to d 3.22e3.25 ppm
and d 3.35e3.38 ppm in case of ITCSUL. The downfield shift in
1H NMR observed for ITCSUL salt in comparison to ITC can be
attributed to the deshielding effect caused due to salt forma-
tion at piperazine nitrogen atoms.3.2. Mass spectrum
ITCSUL salt exhibits amolecular (Mþ þ 1) ion peak at 705.53m/
z corresponding to molecular weight of ITC confirming the
integrity of the parent molecule after salt formation (Fig. 2).3.3. FTIR spectrum
FTIR spectrum for ITCSUL showed the characteristic sulfate
asymmetric SO3 stretch band at 1121 cm
1, the peak which
was not present in spectra of ITC base, affirming the incor-
poration of sulfate ions in ITC molecule (Fig. 3). The broad
band at 3406 cm1 may be associated to OeH stretch due to
presence of traces of water molecules in ITCSUL.Fig. 3 e FTIR spectra of: ITC (A) and ITCSUL (B).
Fig. 4 e DSC overlay plot of: ITC (A) and ITCSUL (B).
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DSC thermograms of ITC and ITCSUL are presented in Fig. 4.
Characteristic sharp melting endotherm of ITC was observed
at 170 C, in agreement with the melting point of ITC. The
decomposition exotherm initiated at 350 C. On the other
hand, DSC thermogram of ITCSUL depicted initial broad
endotherm below 100 C possibly due to presence of trace
solvent. At 185 C, glass transition was observed followed by a
broad endotherm initiating from 238 to 312 C and finally
decomposition exotherm starting at 340 C.
3.5. X-ray diffractogram
The X-ray diffractograms are shown in Fig. 5. The XRPD pat-
terns for ITC exhibited sharp characteristic peaks which can
be used as a fingerprint whereas ITCSUL showed a halo
pattern indicating the amorphous nature of the salt.
3.6. Scanning electron micrographs
The scanning electron micrographs are presented in Fig. 6.
The SEM images of ITC illustrated its acicular needles. On theFig. 5 e X-ray diffractograms oother hand ITCSUL exhibited irregularly shaped particles
distinctly smaller in size.3.7. Hot stage micrographs
The results of hot stage microscopy are shown in Fig. 7.When
viewed in polarized light, ITC produced sharp birefringence
pattern depicting the crystalline nature of the sample. The ITC
crystals started melting at a temperature of 172 C and the
melting was completed at 176 C and decomposition was
observed above 350 C. However, ITCSUL showed no bire-
fringence when viewed under polarized light further the loss
of crystalline nature after salt formation. No sharp melting
was observed and the decomposition was observed above
340 C.3.8. Dynamic light scattering
The DLS technique showed prominent reduction in particle
size of the drug after salt formation (Fig. 8).3.9. Powder flow and compressibility parameters
The powder flow and compressibility parameters are
explained in Table 1. The mean values of bulk density and
tapped density were increased for ITCSUL in comparison to
ITC. Therefore, the ITCSUL salt sample exhibited heavier
particles than ITC. Carr’s index and Hausner ratio have been
widely used to estimate the flow properties of powders. A
Hausner’s ratio value of less than 1.20 indicates good flow
whereas above 1.5 indicates poor flow. Similarly Carr’s index
value less than 15% indicates good flow and the value greater
than 25% indicates poor flow. The Hausner’s ratio of ITC was
1.191 which increased to 1.745 for ITCSUL. Also, the value of
compressibility index of ITCSUL was found to be more than
twice the value of ITC. This reflects the poorer flow properties
of the salt in comparison to ITC. However, flow characteristics
of the salt were improved after ITCSUL-CD mixtures as
demonstrated by their reduced Hausner’s ratio values of
1.63e1.24 and compressibility index values of 14.00e19.33.f: ITC (A) and ITCSUL (B).
Fig. 6 e SEM images of: ITC at 10003magnification (A) and 50003magnification (B); and ITCSUL at 10003magnification (C)
and 50003 magnification (D).
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The solubility study revealed remarkable increase in solubility
of salt as compared to ITC (Fig. 9). The aqueous solubility of
ITC which is reported to be 1 ng/ml [22] was enhanced to
23,000 times after ITCSUL salt formation. Also in comparison
to free base, about 275 and 7 fold increase of solubility in
ethanol and propylene glycol respectively were observed for
ITCSUL.Fig. 7 e The HSM images of: ITC depicting acicular crystal habit p
by decomposition above 350 C (C). Hot stage micrographs of: IT
melting but decomposition above 340 C (E).3.11. Antifungal susceptibility study
Four common fungal strains causing infections in humans
were used to determine susceptibility against ITCSUL. The
MIC for ITC and ITCSUL exhibited no difference (MIC observed
were 0.5, 0.25, 0.25 and 0.25, respectively for A. fumigates, T.
rubrum, M. canis and M. gypsum), and hence no loss of anti-
fungal efficacy of the drug against all four fungal strains
studied. In addition to this, the broth microdilution study alsorior to melting (A), melting initiating at 172 C (B), followed
CSUL revealing amorphous particles (D), and no sharp
Fig. 8 e Particle size distributions of: ITC (A) and ITCSUL (B).
ITC exhibited a particle size of 94.8 mm whereas that of
ITCSUL was found to be 52.1 mm.
a s i a n j o u r n a l o f p h a rma c e u t i c a l s c i e n c e s 9 ( 2 0 1 4 ) 8e1 614elucidated the order of antifungal activity of ITCSUL which
was found to have similar hierarchy of antifungal activity as
ITC.3.12. Dissolution study
The dissolution profiles of ITC, ITCSUL and respective CD
mixtures in simulated gastric fluid are represented in Fig. 10. It
was observed that only about 8.40% of drug was released from
free base form in 3 h, whereas from ITCSUL salt form
approximately 26.4% drug was released in the same time.
Thus, more than 3 fold enhancement of dissolution from
ITCSUL in comparison to ITC was achieved. It was found that
physical mixtures of ITC with different ratios of and b-CD and
HP-b-CD resulted in enhancement of drug release with a
maximum of about 2 fold using ITC HP-b-CD (17.54%) in 1:3 M
ratio.Table 1 e List of powder flow and compaction parameters (me
Entries BD (g/ml) TD (g/ml)
ITC 0.126 0.150  0.002
ITCSUL 0.189 0.329  0.003
ITC-b-1 0.481 0.614  0.004
ITC-b-2 0.615 0.763  0.005
ITC-b-3 0.722 0.856  0.012
ITC-HP-b-1 0.378 0.462  0.006
ITC-HP-b-2 0.464 0.563  0.008
ITC-HP-b-3 0.512 0.607  0.004
ITCSUL-b-1 0.559 0.692  0.004
ITCSUL-b-2 0.670 0.811  0.015
ITCSUL-b-3 0.702 0.817  0.010
ITCSUL-HP-b-1 0.378 0.461  0.006
ITCSUL-HP-b-2 0.463 0.543  0.004
ITCSUL-HP-b-3 0.512 0.597  0.004The CD physical mixtures of ITCSUL exhibited noticeable
enhancements. In case of ITCSUL with b-CD physical mix-
tures, 1:1, 1:2 and 1:3 M ratios provided around 44.7, 51.8 and
59.5% drug released in 3 h respectively. Whereas, the ITCSUL
HP-b-CD in 1:1, 1:2 and 1:3 ratios exhibited approximately 53.6,
60.0 and 65.5% drug release in 3 h respectively.
Table 2 depicts the dissolution rate parameters for ITC,
ITCSUL and their CD physical mixtures. Superior percent re-
leases in 10 min were reported for both types of CD mixtures
of ITCSUL as compared to ITC and its CD mixtures. From the
commercial capsule, 16.25% drug was released in 10 min
whereas, higher DP10 values using ITCSUL with b-CD physical
mixtures (10.1e21.6% approximately) and ITCSUL with HP-b-
CD physical mixtures (19.7e37.8% approximately) were
achieved.
T50% is considered as the factor, describing the dissolution
rate of drug and it was observed that ITCSUL-b-3 and all molar
ratios of ITCSUL with HP-b-CD physical mixtures showed
lesser T50% values of all CD physical mixtures of ITCSUL were
markedly lesser than Candistat suggesting instant release of
drug from these physical mixtures, and slow release from
Candistat.
The DE% in 180 min was enhanced clearly for both ITCSUL
and ITCSUL CD physical mixtures in comparison to ITC and
ITC CDmixtures. The DE% value of ITC was only 5.11%, which
was improved after physical mixtures were prepared with b-
CD and HP-b-CD, and the maximum DE% was nearly 15% for
ITC-b-CD-3. The three molar ratios, 1:1, 1:2 and 1:3 of ITCSUL
with b-CD physical mixtures exhibited DE% of 38.00, 44.55 and
53.07 respectively. While, the values of DE% for ITCSUL with
HP-b-CD physical mixtures in 1:1, 1:2 and 1:3 M ratios were
48.06, 54.51 and 60.25% respectively. Thus, the DE% values of
ITCSUL with b-CD and ITCSUL with HP-b-CD mixtures were
found to be manifold than that of plain ITCSUL (17.31%). Also,
it was found that DE% of ITCSUL-HP-b-3 was higher than that
of Candistat (58.70).
Two factor ANOVA was performed to assess the influence
of two factors explicitly salt formation and increasing cyclo-
dextrin content in physical mixtures on dissolution profile.
The results of two factor ANOVA showed significant (P< 0.001)
enhancement of percent drug dissolved in 3 h for the two
factors studied.an ± SD, n[ 3).
Hausner’s ratio Compressibility index
1.191  0.014 16.000  1.000
1.745  0.046 42.6671.528
1.277  0.009 21.667  0.577
1.239  0.009 19.333  0.577
1.186  0.164 15.667  1.155
1.220  0.149 18.000  1.000
1.215  0.017 17.667  1.154
1.185  0.008 15.667  0.577
1.240  0.009 19.333  0.577
1.210  0.577 17.333  0.577
1.163  0.014 14.000  1.000
1.219  0.015 18.000  1.000
1.172  0.008 14.667  0.577
1.167  0.008 14.333  0.577
Fig. 9 e Solubility (mean ± SD, n[ 3) in various solvents of:
ITC (A) and ITCSUL (B).
Table 2 e The cumulative percent drug released in 10min
(DP10, %), T50% (min), DE% and f2 values of ITC, ITCSUL,
Candistat and CD mixtures in various molar ratios.
Entries DP10 (%) T50% (min) DE% f2
ITC 1.37 e 5.11 14
ITCSUL 1.69 e 17.31 18
Candistat 16.25 30.7 58.70 e
ITC-b-1 2.93 e 9.42 16
ITC-b-2 3.82 e 10.24 17
ITC-b-3 4.01 e 12.39 18
ITC-HP-b-1 3.62 e 10.60 17
ITC-HP-b-2 5.38 e 12.47 18
ITC-HP-b-3 6.95 e 14.82 19
ITCSUL-b-1 10.13 e 38.00 35
ITCSUL-b-2 15.41 58.9 44.55 44
ITCSUL-b-3 21.60 26.6 53.07 56
ITCSUL-HP-b-1 19.69 28.9 48.06 50
ITCSUL-HP-b-2 24.41 23.3 54.51 53
ITCSUL-HP-b-3 37.80 13.9 60.25 43
a s i a n j o u rn a l o f p h a rma c e u t i c a l s c i e n c e s 9 ( 2 0 1 4 ) 8e1 6 15The similarity factor f2 values of CD mixtures of ITCSUL
were found to be better than ITC, ITC CDmixtures and ITCSUL
inferring considerable sameness of dissolution profile of ITC-
SUL-b-3, ITCSUL-HP-b-1 and ITCSUL-HP-b-2 to that of com-
mercial capsules.
According to modified Noyes Whitney equation, the rate
of dissolution of a drug is directly proportional to available
surface area for dissolution and solubility of the compound
in dissolution medium. In our studies we observed sub-
stantial decrease in particle size of ITC after salt formation
was described by DLS, optical microscopy and SEM images.
Also, solubility studies indicated better solubility of ITCSUL
than ITC free base in SGF. Thus, both parametersFig. 10 e Dissolution profiles of: ITC and ITC CD physical
mixtures (A); and ITCSUL, ITCSUL CD physical mixtures
and Candistat (B).influencing the dissolution rate were improved due to salt
formation.
In addition, changing a crystalline form to amorphous
state is one of the most popular approaches to improve solu-
bility and dissolution of poorly soluble drugs. The loss of
crystalline nature of ITC after salt formationwas illustrated by
XRPD patterns, SEM images as well as thermal analytical
techniques.
Also, the inclusion phenomenon of cyclodextrins on ITC-
SUL in presence of an aqueous medium as explained by Tao
et al. can be another major reason for this amplification in
dissolution rate [15]. This effect was more prominent in case
of physical mixtures of ITCSUL and HP-b-CD than in ITCSUL
and b-CD which may be explained on the basis of better
aqueous solubility of HP-b-CD as compared to b-CD.4. Conclusion
Based on the present results, it could be concluded that
preparation of ITCSUL requires a facile single step and
economical process. The physicochemical properties were
modified after salt formationwithout impeding the antifungal
action of the drug against tested pathogenic fungal strains.
The better solubility of ITCSUL than ITC in various pharma-
ceutical solvents, and the enhanced dissolution profiles of the
salt as well as its CD physical mixtures in comparison to ITC
(and its CD mixtures) emphasize the extensive investigation
of the salt as a candidate for clinical use. As the itraconazole is
a BCS Class II drug, its bioavailability is dissolution rate
limited. Therefore, ITCSUL salt may provide excellent tools for
designing variety of oral conventional as well as novel drug
delivery systems.4.1. Itraconazolium sulfate (ITCSUL)
Yield 90%; pale white solid; 1H NMR (CDCl3, 400 MHz):
d 0.88e0.92 (t, 3H, CH3, J ¼ 7.40 Hz), 1.38e1.40 (d, 3H, CH3,
J ¼ 6.72 Hz), 1.60e1.92 (m, 2H, CH2), 3.22e3.25 (d, 4H,
a s i a n j o u r n a l o f p h a rma c e u t i c a l s c i e n c e s 9 ( 2 0 1 4 ) 8e1 616piperazine CH2, J ¼ 9.96), 3.35e3.38 (d, 4H, piperazine CH2,
J ¼ 10), 3.47e3.51 (m, 1H, CH), 3.78e3.83 (m, 2H, dioxolane
CH2), 3.90e3.94 (m, 1H, dioxolane CH), 4.25e4.39 (m, 2H,
NeCH2), 4.74e4.86 (m, 2H, OeCH2), 6.79e6.81 (d, 2H, 2
AreH, J ¼ 10.88 Hz), 6.93e6.95 (d, 2H, 2 AreH, J ¼ 9.08 Hz),
7.03e7.05 (d, 2H, 2 AreH, J ¼ 9.04 Hz), 7.41e7.43 (d, 2H, 2
AreH, J ¼ 6.96 Hz), 7.47e7.48 (d, 1H, AreH, J ¼ 6.06 Hz),
7.56e7.58 (d, 1H, AreH, J ¼ 8.44 Hz), 7.61 (s, 1H, triazolone
CH), 7.89 (s, 1H, triazole CH), 8.20 (s, 1H, triazole CH). MS
(APCI): 705.53 (Mþ1). Anal. Calcd. for C35H40Cl2N8O8S: C,
52.30; H, 5.02; N, 13.94; O, 15.93; S, 3.99. Found: C, 52.61; H,
4.93; N, 14.14; O, 16.10; S, 4.25.Acknowledgment
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